Related Experiment Videos
Rhesus sensitization after midtrimester genetic amniocentesis
H Brandenburg1, M G Jahoda, L Pijpers
1Department of Clinical Genetics, Academic Hospital Dijkzigt, Erasmus University, Rotterdam, The Netherlands.
American Journal of Medical Genetics
|February 1, 1989
Summary
Routine rhesus immunoglobulin (anti-D) administration effectively prevents Rh sensitization in Rh-negative patients after genetic amniocentesis. A 100-microgram dose proved sufficient in 944 patients studied.
Area of Science:
- Obstetrics and Gynecology
- Immunology
- Genetics
Background:
- Rh sensitization poses a risk during pregnancy, particularly after invasive procedures.
- Genetic amniocentesis is a diagnostic tool used in prenatal care.
- Preventing Rh isoimmunization is crucial for fetal health in Rh-negative mothers.
Purpose of the Study:
- To evaluate the efficacy of rhesus immunoglobulin (anti-D) in preventing Rh sensitization.
- To determine the effectiveness of a standard 100-microgram dose of anti-D prophylaxis.
- To assess the safety and utility of anti-D post-genetic amniocentesis.
Main Methods:
- A cohort of 944 Rh-negative patients undergoing genetic amniocentesis was studied.
- Patients received a prophylactic dose of 100 micrograms of rhesus immunoglobulin (anti-D).
- Post-procedure Rh sensitization was monitored.
Main Results:
- No cases of Rh sensitization were observed in the 944 patients.
- The 100-microgram dose of anti-D was found to be completely effective.
- The intervention demonstrated a 100% success rate in preventing Rh isoimmunization.
Conclusions:
- Routine administration of 100 micrograms of rhesus immunoglobulin (anti-D) is highly effective.
- This prophylactic measure successfully prevents Rh sensitization following midtrimester genetic amniocentesis.
- Anti-D prophylaxis is a critical component of care for Rh-negative women undergoing amniocentesis.